Suchergebnisse - "PD-1 inhibition"

PubPharm (59)

1

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

enthalten in: Molecular cancer | 2024

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +14

2

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

enthalten in: Molecular cancer | 2024

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +14

3

Adjuvant immunotherapy for melanoma patients : progress and opportunities

enthalten in: ESMO open | 2024

von Sussman, T. | Ott, P.

4

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Rijnders, M. | Robbrecht, D. | Oostvogels, A. | +11

5

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

enthalten in: Frontiers in immunology | 2023

von Puyalto, A. | Rodríguez-Remírez, M. | López, I. | +12

6

A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

in: Frontiers in Immunology | 2023

von Ander Puyalto | Ander Puyalto | Ander Puyalto | +34

7

Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy : a case report

enthalten in: Gland surgery | 2022

von Li, S. | Zhang, J. | Du, W. | +2

8

Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors

enthalten in: International journal of urology : official journal of the Japanese Urological Association | 2022

von Chen, B. | Kao, C. | Xu, T. | +12

CommentIn: Int J Urol. 2022 Sep;29(9):954-955. - PMID 35411635

9

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

enthalten in: Cancer immunology immunotherapy | 2022

von Rijnders, M. | Robbrecht, D. | Oostvogels, A. | +11

10

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

enthalten in: Cancer immunology immunotherapy | 2022

von Rijnders, M. | Robbrecht, D. | Oostvogels, A. | +11

1
2
3
4
5
6
Nächster »
[6]